News & Events CTI Clinical Trial and Consulting Services Announces Jim Westerkamp promoted to Executive Director, Consulting Management

CTI Clinical Trial and Consulting Services Announces Jim Westerkamp promoted to Executive Director, Consulting Management

March 10, 2014

FOR IMMEDIATE RELEASE [Cincinnati, OH ~ March 10, 2014] CTI Clinical Trial and Consulting Services (CTI) announces Jim Westerkamp has been promoted to Executive Director, Consulting Management.

Jim has been a critical team member at CTI, contributing to its growth and success since he joined the company in 2006. He is responsible for the management of the consulting department and most recently assisted with the integration of the newly acquired S2 Statistical Solutions, Inc. group to CTI. Jim has been instrumental in leading the consulting department, mentoring research associates and junior staff members, participating in business development activities, and managing clients. Jim has more than 25 years of academic and industry experience, including time as a Certified Histocompatibility Specialist and as a molecular laboratory manager at The Ohio State University Medical Center.  Prior to joining CTI, Jim served as a Medical Science Liaison at Astellas Pharma US, Inc.

“We are proud to recognize Jim’s contributions to our collective success, and he will continue to aid in CTI’s global expansion and innovative leadership,” said Lynn Fallon, President. “We’re looking forward to the continued value he will bring to CTI in the future.”

 

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious   diseases, hematology,  cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.

Subscribe to our mailing list

* indicates required